Hang in there!!, page-129

Nice selections for success you have there, have you checked BOT as well, it excites me greatly, but I think OPT has the potential to wake me up at night with future news flow. Looming news flow which i see tripling the current share price prior to Phase 3 readout is the mid-cycle review (Oct/November). Remember, OPT had 300 in Phase 2b trials, some companies run these with 30 participants, and 300 in total for Phase 3. OPT are making sure they slam-dunk their Phase 3 trial with 900 participants. The Phase 2b results showed a strong statistical improvements in eyesight, with enough participants to actually complete what woyld normally be a Phase 3 study.
But the thing I like most about OPT is that due to it being mixed with a drug already on the market, the uptake should be 100%, why would a doctor provide the standard of care without also utilizing OPT's product knowing that if it is used in conjunction it will provide a statistically significant improvement. So OPT once approved will be used as a combination therapy for the entire $19B market.
OPT excites me with what it will look like post Phase 3 readout in 15 months, and between Phase 3 and Phase 3 mid-cycle reviews is where the huge gains start. Good luck all